OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 17 ENHANCING OUR STRATEGIC PORTFOLIO BIOGEN 2021 YEAR IN REVIEW (aducanumab-avwa), the first approved treatment under accelerated pathway that is directed at an underlying pathophysiology of Alzheimer’s disease and the first novel therapy approved for Alzheimer’s disease since 2003. Alzheimer’s disease Despite 30 years of investment by the pharmaceutical industry, Alzheimer’s disease – which affects an estimated 32 million people worldwide along with their families, friends, caregivers and health systems – has seen very little progress in treatment. In June 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Biogen’s and Eisai Co., Ltd.’s (Eisai) aducanumab-avwa, marketed as ADUHELM® for the treatment of Alzheimer’s disease. t h e m o s t c o m p l e x a n d d e v a s t a t i n g d i s e a s e s . W e p i o n e e r n e u r o s c i e n c e a n d d r i v e i n n o v a t i o n t o d e f e a t C a r i n g d e e p l y . W o r k i n g f e a r l e s s l y . C h a n g i n g l i v e s . TO SERVE HUMANITY THROUGH SCIENCE Neurology Expanding on Biogen’s leadership in neuroscience with a diversified pipeline Building a multi-franchise business Specialized Immunology Delivering first-in-class and best-in- class lupus therapies Biosimilars Providing patient access to innovative medicines and contributing to healthcare sustainability Digital Health Accelerating efforts to build complementary digital solutions and technologies to potentially predict, measure and prevent disease ADUHELM is the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. Accelerated approval was granted based on data from clinical trials demonstrating the effect of ADUHELM on reducing amyloid beta plaques, a biomarker that is reasonably likely to predict clinical benefit, in this case a reduction in clinical decline. Þ READ MORE ABOUT ADUHELM’S ACCELERATED APPROVAL In April 2022, we were disappointed to receive the final coverage determination by the Centers for Medicare & Medicaid Services (CMS) that would exclude Medicare reimbursement for the majority of Alzheimer’s disease patients. To avoid any treatment interruptions following the CMS decision, Biogen initiated a program for all U.S.